Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells

Phosphoinositide-3 kinase alpha-specific inhibitors (PI3Kαi) displayed promising potential for the treatment of esophageal squamous cell carcinoma (ESCC) with frequent activation in PI3K signaling. However, acquired resistance is likely to develop and limit the efficacy of PI3Kαi like other targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu-xiang, Zhang, Xu, Ma, Qing-yang, Hu, Lan-dian, Zhang, Xi, Wang, Yi, Xu, Lan, Yang, Chun-hao, Tan, Cun, Kong, Xiang-yin, Ding, Jian, Meng, Ling-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809409/
https://www.ncbi.nlm.nih.gov/pubmed/33446653
http://dx.doi.org/10.1038/s41419-020-03370-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809409/
https://www.ncbi.nlm.nih.gov/pubmed/33446653
http://dx.doi.org/10.1038/s41419-020-03370-4

Ejemplares similares